Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Curex
WARNING LETTER
•Curex•August 1, 2025

Curex – FDA Warning Letter, Aug 1, 2025

Record Details

In September 2025, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to Curex, based in Miami, Florida, following a review of the company"s website in August 2025. The FDA identified significant violations regarding the marketing of compounded drug products, specifically semaglutide and tirzepatide. According to the letter, Curex made false or misleading claims that these compounded drugs are the same as FDA-approved medications like Ozempic, Wegovy, and Mounjaro. The agency noted that since compounded drugs do not undergo the same rigorous approval process as brand-name medications, claiming they have "the same active ingredients" or "clinically proven success" is deceptive. Under the regulatory framework of the Federal Food, Drug, and Cosmetic Act (FDCA), these products are considered misbranded. The FDA stated that introducing such misbranded drugs into interstate commerce is a violation of federal law. To resolve these issues, Curex is required to take immediate action to remove any misleading language from its marketing materials and ensure all operations comply with FDA regulations. The company must investigate the root cause of these violations and implement measures to prevent their recurrence. Curex is required to provide a written response to the FDA within fifteen working days, detailing the specific steps taken to address the violations and including supporting documentation. Failure to comply with these requirements may result in legal action, including product seizures or injunctions.

Company
Curex
Inspection date
August 1, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · 91a081d8-0e6b-4c15-80ae-bb6146c778ca

Violation Codes10
21 U.S.C. 331(c)21 U.S.C. 352(a)FD&C Act 201(p)FD&C Act 502(bb)21 U.S.C. 352(bb)FD&C Act 201(g)(1)FD&C Act 502(a)21 U.S.C. 321(g)(1)21 U.S.C. 321(p)FD&C Act 301(a)

Full citation text and observation details available on the Dashboard.

Other documents for Curex
  • WARNING_LETTER - 2025-08-31August 31, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Curex
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.